Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Levofloxacin

FDA-approved product (tablet, oral), marketed as Iquix, Levaquin, Levaquin In Dextrose 5% In Plastic Container and 3 more.

Registered studies
50+
Lab records
143
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Levofloxacin
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Bacterial conjunctivitis
  • Bacterial disease
  • Chronic bronchitis
  • Cystic fibrosis
  • Eye infection
  • Infection
  • Pneumonia
  • Respiratory tract infectious disorder
  • Sinusitis
  • Urinary tract infection

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Fluoroquinolones
FDA pharmacologic class
Fluoroquinolone Antibacterial FDA label ↗
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC J01MA12; WHO ATC S01AE05; FDA class Fluoroquinolone Antibacterial

Repurposing investigation

Levofloxacin is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA97.4% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • E. coli>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • K. pneumoniae>99% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.
  • M. tuberculosis91.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • MRSA: measured active in 1 of 1 lab record
  • E. coli: measured active in 7 of 7 lab records
  • K. pneumoniae: measured active in 128 of 131 lab records
  • M. tuberculosis: measured active in 4 of 4 lab records
Open Levofloxacin in ChEMBL Registered studies below
Show the 143 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-7.6 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Levofloxacin with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections

    NCT01978938 · start 2014-10-06

    Registered record
    Registry ID
    NCT01978938
    Conditions
    cUTI
    Interventions
    Eravacycline; Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2014-10-06
    Completion
    2015-08-21
    Enrolment
    908

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditioncUTI
    InterventionEravacycline; Levofloxacin
    PhasePhase 3
    Registry statusCompleted

  • Genotypic Resistance Guided Therapy in Helicobacter Pylori Eradication

    NCT01725906 · start 2012-11

    Registered record
    Registry ID
    NCT01725906
    Conditions
    Self Efficacy
    Interventions
    empirical therapy; Genotypic resistance guided therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2012-11
    Completion
    2017-12
    Enrolment
    450

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSelf Efficacy
    Interventionempirical therapy; Genotypic resistance guided therapy
    PhasePhase 4
    Registry statusUnknown

  • Personalized Treatment for Refractory H Pylori Infection

    NCT02547025 · start 2012-08-01

    Registered record
    Registry ID
    NCT02547025
    Conditions
    Helicobacter Pylori Infection
    Interventions
    rabeprazole+3 antibiotics; rabeprazole+bismuth+2 antibiotics; rabeprazole+amox+tetr+levo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-08-01
    Completion
    2021-10-31
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    Interventionrabeprazole+3 antibiotics; rabeprazole+bismuth+2 antibiotics; rabeprazole+amox+tetr+levo
    PhaseNot applicable
    Registry statusCompleted

  • Rechallenge, Potential Drug Induced Liver Injury (Kaiser)

    NCT01584765 · start 2012-02

    Registered record
    Registry ID
    NCT01584765
    Conditions
    Drug-induced Liver Injury
    Interventions
    Prescription drugs with known hepatotoxicity
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2012-02
    Completion
    2013-04
    Enrolment
    1

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-induced Liver Injury
    InterventionPrescription drugs with known hepatotoxicity
    PhaseNot recorded
    Registry statusCompleted

  • A Study of Sodium Carboxymethylcellulose for Post Cataract Surgery Dry Eye Symptoms

    NCT02028754 · start 2011-07

    Registered record
    Registry ID
    NCT02028754
    Conditions
    Dry Eye Syndromes; Cataract
    Interventions
    Sodium Carboxymethylcellulose; Levofloxacin; Prednisolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2011-07
    Completion
    2013-05
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDry Eye Syndromes; Cataract
    InterventionSodium Carboxymethylcellulose; Levofloxacin; Prednisolone
    PhasePhase 4
    Registry statusCompleted

  • 5 Day Concomitant Versus 10 Day Sequential Therapy for Eradication of H. Pylori Infection

    NCT01544517 · start 2011-01

    Registered record
    Registry ID
    NCT01544517
    Conditions
    Helicobacter Pylori Infection
    Interventions
    Eradication therapy (amoxicillin; esomeprazole; tinidazole; levofloxacin)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2011-01
    Completion
    2011-12
    Enrolment
    180

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHelicobacter Pylori Infection
    InterventionEradication therapy (amoxicillin; esomeprazole; tinidazole; levofloxacin)
    PhasePhase 3
    Registry statusCompleted

  • MP-376 (Aeroquin™, Levofloxacin for Inhalation) in Patients With Cystic Fibrosis

    NCT01180634 · start 2010-11-04

    Registered record
    Registry ID
    NCT01180634
    Conditions
    Cystic Fibrosis
    Interventions
    Aeroquin; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-11-04
    Completion
    2012-05-07
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCystic Fibrosis
    InterventionAeroquin; Placebo
    PhasePhase 3
    Registry statusCompleted

  • The Efficacy of Sequential Therapy as Second Line Therapy for Refractory Helicobacter Pylori Infection - A Pilot Study

    NCT00885417 · start 2009-04

    Registered record
    Registry ID
    NCT00885417
    Conditions
    H. Pylori Infection
    Interventions
    Cravit-based sequential therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2009-04
    Completion
    2010-12
    Enrolment
    142

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionH. Pylori Infection
    InterventionCravit-based sequential therapy
    PhasePhase 4
    Registry statusCompleted

  • Ocular Availability in Human Tears After Topical Administration of 1.5% Levofloxacin Compared to Active Comparators

    NCT00703313 · start 2008-05

    Registered record
    Registry ID
    NCT00703313
    Conditions
    Healthy
    Interventions
    1.5% levofloxacin ophthalmic solution; 0.5% moxifloxacin hydrochloride ophthalmic solution; 0.3% gatifloxacin ophthalmic solution
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2008-05
    Completion
    Not recorded
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    Intervention1.5% levofloxacin ophthalmic solution; 0.5% moxifloxacin hydrochloride ophthalmic solution; 0.3% gatifloxacin ophthalmic solution
    PhasePhase 4
    Registry statusCompleted

  • Granuloma Annulare Treated With Rifampin, Ofloxacin, and Minocycline Combination Therapy

    NCT00720980 · start 2008-05

    Registered record
    Registry ID
    NCT00720980
    Conditions
    Granuloma Annulare
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2008-05
    Completion
    2008-07
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGranuloma Annulare
    InterventionNot recorded
    PhaseNot recorded
    Registry statusCompleted

  • Enteroaggregative E.Coli (EAEC)

    NCT00362869 · start 2008-02

    Registered record
    Registry ID
    NCT00362869
    Conditions
    Escherichia Coli Infections
    Interventions
    Levofloxacin; Placebo; Enteroaggregative E. coli (EAEC)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2008-02
    Completion
    2008-12
    Enrolment
    5

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEscherichia Coli Infections
    InterventionLevofloxacin; Placebo; Enteroaggregative E. coli (EAEC)
    PhasePhase 1
    Registry statusTerminated

  • Pilot Study of the Safety and Clinical Efficacy of Topical Dermacyn™ Wound Care to Treat Mild Diabetic Foot Infections

    NCT00516958 · start 2007-05

    Registered record
    Registry ID
    NCT00516958
    Conditions
    Foot Ulcer, Diabetic
    Interventions
    Topical Dermacyn; Topical Dermacyn and Levofloxacin; Topical Saline and Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-05
    Completion
    2007-12
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFoot Ulcer, Diabetic
    InterventionTopical Dermacyn; Topical Dermacyn and Levofloxacin; Topical Saline and Levofloxacin
    PhasePhase 2
    Registry statusCompleted

  • Protection From Cisplatin Ototoxicity by Lactated Ringers

    NCT00584155 · start 2006-07

    Registered record
    Registry ID
    NCT00584155
    Conditions
    Hearing Loss
    Interventions
    Normal Saline and 0.3% ofloxacin; Lactated Ringer's with 0.03% Ofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Withdrawn
    Start
    2006-07
    Completion
    2010-06
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHearing Loss
    InterventionNormal Saline and 0.3% ofloxacin; Lactated Ringer's with 0.03% Ofloxacin
    PhasePhase 1
    Registry statusWithdrawn

  • Study of Efficacy of Levofloxacin 0.5% Ophthalmic Solution Administered Three Times a Day for Bacterial Conjunctivitis

    NCT00565123 · start 2004-09

    Registered record
    Registry ID
    NCT00565123
    Conditions
    Bacterial Conjunctivitis
    Interventions
    0.5% levofloxacin eye drops; 0.5% levofloxacin eye drops
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2004-09
    Completion
    2006-01
    Enrolment
    119

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBacterial Conjunctivitis
    Intervention0.5% levofloxacin eye drops; 0.5% levofloxacin eye drops
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • Safety and Efficacy of Floxin Otic Solution in the Treatment of Acute Otitis Media in Children

    NCT00781521 · start 2002-11

    Registered record
    Registry ID
    NCT00781521
    Conditions
    Otitis Media
    Interventions
    ofloxacin otic solution 0.3%
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2002-11
    Completion
    2003-04
    Enrolment
    96

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOtitis Media
    Interventionofloxacin otic solution 0.3%
    PhasePhase 3
    Registry statusCompleted